SCHEMBL14916951

SCHEMBL14916951

Cn1cc(-n2ccc(=O)c(COc3ccc4ncc(C(=O)O)cc4c3)n2)cn1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MET P08581 7/20 0.41
PDE10A Q9Y233 1/20 0.36
FGFR2 P21802 3/20 0.36
FGFR3 P22607 3/20 0.36
FGFR1 P11362 1/20 0.36
MAP4K4 O95819 1/20 0.36
EGLN1 Q9GZT9 2/20 0.35
BCL2 P10415 1/20 0.35
MCL1 Q07820 1/20 0.35
MGAM O43451 1/20 0.35
ALKBH1 Q13686 1/20 0.35
KDR P35968 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
FGFR4 P22455 1/20 0.35
MAOB P27338 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14916275 0.99 MET (0.41) METPDE10AFGFR2FGFR3FGFR1
SCHEMBL368325 0.92 MET (0.43) METPDE10AFGFR2FGFR3FGFR1
Lithium Ion SCHEMBL14916273 0.92 MET (0.36) METPDE10AFGFR2FGFR3FGFR1
SCHEMBL255618 0.90 PDE10A (0.38) METPDE10AFGFR2FGFR3FGFR1
Hydrochloric Acid SCHEMBL174468 0.89 PDE10A (0.37) METPDE10AFGFR2FGFR3FGFR1
SCHEMBL359817 0.88 MET (0.40) METPDE10AFGFR2FGFR3FGFR1
SCHEMBL360598 0.88 PDE10A (0.38) METPDE10AFGFR3FGFR1
SCHEMBL178094 0.88 MET (0.44) METFGFR3FGFR1
SCHEMBL359139 0.88 MET (0.36) METPDE10AFGFR2FGFR3FGFR1
SCHEMBL10283524 0.88 HPGD (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116231-A1 TYROSINE KINASE INHIBITORS ABL1, ERBB2, MET MET 3/4885PDE10A 3303/4885FGFR2 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.